Cardiff Oncology to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Rhea-AI Summary
Cardiff Oncology (Nasdaq: CRDF) will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference in a virtual format on February 25-26, 2026.
Interim CEO Mani Mohindru, PhD will present on 02/25/2026 at 1:20 PM ET. Management will hold 1x1 investor meetings. According to the company, a live webcast and replay will be available via the Events section of the Cardiff Oncology website.
Positive
- None.
Negative
- None.
News Market Reaction – CRDF
On the day this news was published, CRDF gained 2.56%, reflecting a moderate positive market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $3M to the company's valuation, bringing the market cap to $111M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
With CRDF flat on the day, peers show mixed moves: GNLX +2.75%, SKYE +2.96%, ONCY +0.99%, ACTU +0.24%, and AVTX -0.20%. No clear sector-wide pattern ties directly to this conference announcement.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 27 | Phase 2 update | Positive | -32.0% | Positive Phase 2 mCRC data with improved ORR and PFS vs standard of care. |
| Jan 27 | Leadership changes | Negative | -32.0% | CEO and CFO departures with interim CEO appointed during transition to late stage. |
| Dec 08 | Clinical poster data | Positive | +10.9% | Phase 1 CMML trial showed tolerability and preliminary efficacy in about 40% of patients. |
| Dec 08 | Investor conference | Neutral | +10.9% | Sidoti virtual conference presentation with webcast and 1x1 investor meetings. |
| Nov 24 | Investor conference | Neutral | +2.5% | Piper Sandler healthcare conference fireside chat and investor meetings. |
Recent history shows sharp divergence on major positive clinical and leadership updates, with the stock dropping 31.97%, while routine conference appearances and some clinical posters have seen modest to strong gains.
Over the last several months, Cardiff Oncology has balanced investor outreach with advancing onvansertib. On Nov 24, 2025 and Dec 8, 2025, it announced presentations at the Piper Sandler and Sidoti investor conferences, alongside Phase 1 CMML data, with mixed but generally positive price reactions. On Jan 27, 2026, the company reported a strong Phase 2 mCRC update and major leadership changes, yet shares fell 31.97%. Today’s Oppenheimer conference appearance fits the pattern of ongoing investor engagement following those late-stage development signals.
Market Pulse Summary
This announcement highlights Cardiff Oncology’s continued investor outreach as it moves toward late-stage development, with management presenting at the Oppenheimer conference on February 25, 2026. Recent history includes strong Phase 2 data in mCRC and leadership changes on Jan 27, 2026, as well as earlier conference appearances. Investors may watch how messaging around clinical progress, cash of $60.6M, and ongoing losses of $11.3M in Q3 2025 shapes sentiment over time.
Key Terms
plk1 inhibition medical
AI-generated analysis. Not financial advice.
SAN DIEGO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present and participate in 1x1 investor meetings at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, being held in a virtual format February 25-26, 2026.
Details of the presentation can be found below.
Presenter: Mani Mohindru, PhD (Interim CEO)
Date: 02/25/2026
Time: 1:20 PM ET
Interested parties can register for and access the live webcast for the conference by visiting the “Events” section of the Cardiff Oncology website. The webcast replay will be available after the conclusion of the presentation.
About Cardiff Oncology, Inc.
Cardiff Oncology is a clinical-stage biotechnology company advancing innovative cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Our lead asset, onvansertib, is a highly specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, we aim to overcome treatment resistance and deliver improved clinical outcomes for patients.
For more information, please visit https://www.cardiffoncology.com.
Investor Contact:
Candice Masse
Astr Partners
candice.masse@astrpartners.com
Media Contact:
Amy Bonanno
Lyra Strategic Advisory
abonanno@lyraadvisory.com
FAQ
When will Cardiff Oncology (CRDF) present at the Oppenheimer conference in February 2026?
Who is presenting for Cardiff Oncology (CRDF) at the Oppenheimer 36th Annual Healthcare Life Sciences Conference?
How can investors watch Cardiff Oncology's (CRDF) Oppenheimer conference presentation?
Will Cardiff Oncology (CRDF) hold investor meetings at the Oppenheimer conference?
What topics will Cardiff Oncology (CRDF) likely cover in the Oppenheimer presentation on February 25, 2026?
